Chemical manufacturing drives growth in US manufacturing sector, Census Bureau reports

Chemical manufacturing in the United States expanded between 2017 and 2022 even as the broader manufacturing sector saw a decline in establishments, according to new data released by the U.S. Census Bureau.

The agency said the chemical manufacturing subsector – responsible for producing products ranging from medicines and fertilizers to plastics, soap and ink – recorded notable gains in both the number of establishments and the value of shipments during the period covered by the latest Economic Census.

“Most people may not realize the close connection they have with the Chemical Manufacturing industry, but it’s a subsector that helps create commonplace products we all use, from ink and soap to plastics and medicine,” wrote Census Bureau supervisory survey statistician Lynda Lee and writer/editor Travis Shoemaker in the agency’s analysis.

Data from the 2022 Economic Census showed the number of U.S. chemical manufacturing establishments, classified under NAICS 325, rose 10.2% from 13,571 in 2017 to 14,961 in 2022. Over the same period, the total number of manufacturing establishments across all industries declined 1.7%, from 291,586 to 286,626.

The subsector also recorded growth in economic output. The value of shipments for chemical manufacturing increased 22.4%, climbing from about $735.9 billion in 2017 to $901.0 billion in 2022, though the figures were not adjusted for price changes.

According to the Census Bureau, increased industrial production in the pharmaceutical sector played a significant role in that growth. Production workers’ annual hours in the Pharmaceutical and Medicine Manufacturing industry increased from 270.1 million hours in 2017 to 341.6 million hours in 2022.

The North American Industry Classification System defines chemical manufacturing as the transformation of raw materials through chemical processes into new products. The range of activities includes processes such as refining oil into margarine and synthesizing plant compounds like willow bark into medicines such as aspirin.

Historical data from the Census Bureau’s Business Dynamics Statistics show the broader manufacturing sector experienced strong rates of new establishment creation until the early 1990s, when closures began to outnumber startups. 

Within chemical manufacturing, the rate of newly created establishments reached its highest level in 2022, while the rate of closures has also risen in recent years, with 2022 and 2023 marking the highest exit rates in two decades.

Employment trends tied to the industry were mixed. Between 2017 and 2022, the number of pharmacists increased about 28.1%, chemical engineers rose 54.5%, and chemists and materials scientists grew 24.8%. 

At the same time, the number of chemical technicians declined 2.2%. Employment in pharmacies and drug stores also fell by about 5.6% over the period, alongside a decline in the number of establishments in that industry.

Geographically, the chemical manufacturing workforce is concentrated in certain regions. Data from the Census Bureau’s 2023 Annual Integrated Economic Survey showed the largest shares of workers were located in the South, with about 334,398 employees, and the Midwest, with 242,706.

The agency also highlighted variations in market concentration across different chemical manufacturing industries. In petrochemical manufacturing, the four largest firms accounted for about 74.2% of the sector’s $77.6 billion in shipments in 2022, indicating a high level of concentration. 

By comparison, medicinal and botanical manufacturing was less concentrated, with the top four firms accounting for about 24.7% of the industry’s $13.9 billion in shipments.

The Census Bureau said the findings illustrate both the scale and complexity of chemical manufacturing, which plays a central role in producing a wide range of consumer and industrial products across the U.S. economy.

Source link

Flex Announces U.S. Manufacturing Collaboration with AMD

Flex expanded its strategic collaboration with AMD to manufacture the AMD Instinct platform in the United States. This marks a significant milestone in strengthening domestic production of advanced AI and high-performance technologies.

]]>

As part of the collaboration, manufacturing of the AMD Instinct MI355X platform is underway at Flex’s headquarters in Austin, Texas, with volume ramp expected next quarter. 

Flex will also support the next generation of AMD Instinct platforms to meet surging demand for large‑scale AI deployments across data centers.

“Partnering with AMD to manufacture AMD Instinct platforms in the U.S. marks an important milestone in advancing domestic AI infrastructure,” said Rob Campbell, President of Communications, Enterprise and Cloud, Flex. “By combining Flex’s advanced manufacturing capabilities, resilient supply chain, and U.S. footprint with AMD’s leadership in high-performance computing, we’re enabling customers to scale AI faster and with greater reliability.”

Flex manufactures the complete AMD Instinct platform, assembling eight AMD Instinct GPUs along with surrounding components into a single, high-density system design. Each platform undergoes rigorous factory testing and validation, including using advanced liquid-cooling hardware from Flex company JetCool.

“Expanding our U.S. manufacturing presence with Flex for AMD Instinct platforms is an important step in strengthening how we build and deliver for customers,” said Keivan Keshvari, senior vice president, Global Operations & Quality, AMD. “By growing a resilient, agile, and diverse supply chain, we are better positioned to meet AI demand and deliver at scale.”

Source link

Boviet Solar Strengthens Position in U.S. Residential Solar Market with High-Efficiency PV Modules and Expanded Manufacturing

Boviet Solar has reaffirmed its position as a key technology partner for residential solar installations across the United States, supporting a wide range of projects including single-family homes, multi-family developments, and affordable housing communities.

The solar technology company, known for manufacturing high-efficiency monocrystalline photovoltaic cells and modules, provides solutions such as the Gamma Series™ monofacial and Vega Series™ bifacial PV modules designed for residential rooftop and community-level installations. These solutions aim to help homeowners, property developers, and housing authorities achieve energy independence, reduce electricity costs, and gain greater control over energy consumption.

According to the company, residential solar adoption in the United States continues to expand as rising utility costs and sustainability targets drive demand for reliable and durable rooftop systems. Solar installations in residential settings require strong performance, long-term reliability, and predictable energy production, making the selection of dependable module suppliers critical for ensuring long-term system value.

Boviet Solar’s Gamma Series™ modules, powered by advanced monocrystalline PERC and N-Type cell technologies, are designed to deliver high efficiency, improved low-light performance, and optimized rooftop energy generation. The modules are engineered with robust mechanical strength and high resistance to wind and snow loads, enabling reliable performance across diverse climate conditions in the U.S.

The company highlighted that dependable solar systems are particularly important for multi-family housing and affordable housing developments, where solar energy can help reduce operational costs and improve tenant affordability. By lowering common-area electricity expenses and stabilizing long-term operating budgets, solar installations can support property owners and housing authorities in meeting environmental, social, and governance (ESG) goals while expanding access to clean energy.

Boviet Solar’s PV modules have undergone independent validation through third-party testing and industry evaluations. The company’s modules have been recognized as Top Performers in the Kiwa PVEL PV Module Reliability Scorecard since 2019, demonstrating strong performance under rigorous stress testing. Additional factory and product assessments conducted by Black & Veatch have verified the company’s manufacturing quality and operational standards.

The company also maintains a comprehensive compliance portfolio, including certifications from TÜV covering RoHS, REACH, PFAS, TCPL, and TCSA standards. Its modules consistently achieve strong CEC PTC and STC ratings, confirming reliable real-world performance. Each module is backed by a 12-year product warranty (extendable) and a 30-year performance warranty, providing long-term assurance for residential installations.

Boviet Solar’s financial strength and bankability have also received recognition from major global institutions. The company has maintained Tier 1 status from BloombergNEF since 2017, while also receiving an A-Class Global Bankable Manufacturer ranking from Wood Mackenzie and a Top 10 Financial Stability score from Sinovoltaics.

To strengthen supply-chain resilience in the U.S. market, Boviet Solar is expanding its manufacturing footprint. The company is developing a 3.0 GW PV module manufacturing facility in Greenville, North Carolina, expected to be operational in 2025, along with a planned 3.0 GW PV cell manufacturing expansion targeted for 2026. These facilities are expected to shorten supply timelines, improve procurement certainty, support domestic content requirements under U.S. policies, and create skilled local jobs.

Commenting on the company’s role in the residential solar sector, Songul Atacan, Head of Global Brand and Marketing at Boviet Solar, said residential solar goes beyond electricity generation by enabling homeowners, developers, and communities to adopt reliable, affordable, and sustainable energy solutions.

Boviet Solar also emphasized its commitment to sustainability and responsible manufacturing practices. The company operates under ISO 9001, ISO 14001, and ISO 45001 standards, participates in the United Nations Global Compact, and follows supply-chain transparency measures such as the Solar Supply Chain Traceability Protocol, STS audits, and compliance with the UFLPA regulations. It also completes sustainability assessments through EcoVadis.

With gigawatts of solar modules already deployed across the United States, Boviet Solar aims to support residential solar installations that reduce household energy costs, lower carbon emissions, increase property value, and strengthen long-term energy security in communities.

Like this:

Like Loading…

Source link

President Trump Secures Trillions in New U.S. Investments as Companies Expand American Manufacturing

Supporters of President Donald J. Trump say his America First economic policies are driving a massive wave of private investment back into the United States. Since the start of his second term, companies from around the world have announced major plans to expand U.S. manufacturing, artificial intelligence infrastructure, energy production, and advanced technology development.

Advocates of the administration say the investments demonstrate renewed confidence in the U.S. economy and a shift toward onshoring production, strengthening domestic supply chains, and creating American jobs. The announced investments collectively total trillions of dollars, with projects spread across dozens of states.

Below is a non-comprehensive list of companies and projects announcing new U.S.-based investments during President Trump’s second term.

• Apple – $600 billion investment in U.S. manufacturing and workforce training while expanding domestic supply chains.
• Meta – $600 billion investment by 2028 to expand artificial intelligence technology, infrastructure, and workforce development in the U.S.
• Project Stargate (SoftBank, OpenAI, Oracle) – $500 billion private investment in U.S. artificial intelligence infrastructure.
• NVIDIA – $500 billion investment in U.S. AI infrastructure over four years, while manufacturing AI supercomputers in the United States for the first time.
• Amazon – $340 billion invested in the U.S. last year, plus $20 billion for cloud infrastructure in Pennsylvania, $10 billion in North Carolina data centers, and $4 billion across small towns nationwide.
• Micron Technology – $200 billion investment in U.S. semiconductor manufacturing, including facilities in Boise, Idaho, and Manassas, Virginia.
• IBM – $150 billion investment over five years in U.S. manufacturing and technology growth.
• Taiwan Semiconductor Manufacturing Company (TSMC) – $100 billion investment in U.S. chip manufacturing facilities.
• Johnson & Johnson – $55 billion investment in manufacturing, research, and technology, including a major facility in North Carolina.
• AstraZeneca – $50 billion investment in medicines manufacturing and research in the U.S.
• Anthropic – $50 billion investment in AI infrastructure, including new data centers in Texas and New York.
• Roche – $50 billion investment in U.S. research and manufacturing expected to create more than 1,000 permanent jobs and 12,000 construction jobs.
• Bristol Myers Squibb – $40 billion investment in U.S. manufacturing, technology, and research operations.
• GSK – $30 billion investment in U.S. research, development, and manufacturing facilities.
• Eli Lilly – $27 billion investment to more than double U.S. drug manufacturing capacity.
• Hyundai – $26 billion investment, including a $5.8 billion steel plant in Louisiana, creating roughly 1,500 jobs.
• Vantage Data Centers – $25 billion project to build a 1.4-gigawatt data center campus in Texas employing more than 5,000 workers.
• ADQ and Energy Capital Partners – $25 billion investment in U.S. energy and data center infrastructure.
• Google – $25 billion investment in AI and data center infrastructure.
• Blackstone – $25 billion investment in digital and energy infrastructure in Pennsylvania.
• Novartis – $23 billion investment to build or expand ten U.S. manufacturing facilities and create 4,000 jobs.
• John Deere – $20 billion investment over the next decade in American manufacturing expansion.
• DAMAC Properties – $20 billion investment in U.S. data centers.
• CMA CGM – $20 billion investment in shipping and logistics expected to create 10,000 jobs.
• Sanofi – $20 billion investment in research and manufacturing in the U.S.
• Venture Global LNG – $18 billion investment in a Louisiana liquefied natural gas facility.
• Woodside Energy Group – $17.5 billion investment in a new LNG facility in Louisiana.
• GlobalFoundries – $16 billion investment expanding chip manufacturing plants in New York and Vermont.
• FirstEnergy Corp. – $15 billion investment in energy infrastructure improvements.
• Nippon Steel – $14 billion investment in U.S. Steel operations, including a new steel mill.
• Stellantis – $13 billion investment to expand U.S. vehicle production by more than 50 percent.
• Gilead Sciences – $11 billion expansion of U.S. manufacturing investment.
• AbbVie – $10 billion investment over ten years, adding four new manufacturing plants.
• JPMorganChase – $10 billion investment supporting U.S. manufacturing growth.
• Merck & Co. – $9 billion investment in U.S. pharmaceutical manufacturing, including new facilities in Delaware and North Carolina.
• PPL – $6.8 billion investment expanding power grid capacity.
• CoreWeave – $6 billion investment in data center expansion.
• Westinghouse – $6 billion investment to build ten nuclear reactors in the United States.
• Clarios – $6 billion expansion of domestic manufacturing operations.
• UCB – $5 billion investment for a new U.S. pharmaceutical manufacturing plant.
• Ford – $5 billion investment in Kentucky and Michigan manufacturing facilities.
• Pratt Industries – $5 billion investment creating 5,000 manufacturing jobs across four states.
• Hanwha Group – $5 billion investment expanding shipbuilding operations in Philadelphia.
• GlobalWafers – $4 billion investment expanding U.S. semiconductor production.
• General Motors – $4 billion investment shifting vehicle production from Mexico and China to U.S. plants.
• Mitsubishi – $3.9 billion investment in American energy projects.
• Shintech – $3.4 billion expansion of a Louisiana chemical manufacturing facility.
• Regeneron and Fujifilm Diosynth Biotechnologies – $3 billion agreement to expand pharmaceutical manufacturing in North Carolina.
• Kraft Heinz – $3 billion investment upgrading U.S. food manufacturing plants.
• GE Appliances – $3 billion investment expanding manufacturing across five states.
• NorthMark Strategies – $2.8 billion supercomputing facility in South Carolina.
• Thermo Fisher Scientific – $2 billion investment expanding manufacturing operations.
• Amkor Technology – $2 billion semiconductor facility in Arizona, creating 2,000 jobs.
• Biogen – $2 billion investment in North Carolina manufacturing.
• Mars, Inc. – $2 billion expansion of U.S. manufacturing operations.
• GE Aerospace – $2 billion combined investment creating 10,000 jobs nationwide.
• Kimberly-Clark – $2 billion investment expanding manufacturing facilities, including a major plant in Ohio.
• Chobani – $1.7 billion investment, including a new dairy processing plant in New York.
• Oklo – $1.68 billion fuel recycling facility in Tennessee.
• Corning – $1.5 billion expansion of Michigan manufacturing, creating 1,500 jobs.
• Smithfield Foods – $1.3 billion pork processing facility in South Dakota.
• MP Materials – $1.25 billion rare earth magnet facility in Texas.
• First Solar – $1.1 billion solar manufacturing plant in Louisiana.
• Carrier – $1 billion investment creating 4,000 jobs.
• Cencora – $1 billion investment strengthening U.S. distribution networks.
• Siemens Energy – $1 billion expansion of grid and turbine manufacturing.
• Hikma Pharmaceuticals – $1 billion investment expanding research and manufacturing.
• Vaxcyte – $1 billion U.S. vaccine manufacturing investment.
• Anduril Industries – $1 billion autonomous defense systems facility in Ohio.
• Live Nation Entertainment – $1 billion investment building 18 new music venues nationwide.
• Hitachi – $1 billion investment in American energy infrastructure, including a transformer plant in Virginia.
• Williams International – $1 billion aviation engine manufacturing facility in Florida.

Numerous additional companies—including Toyota, Lego, Samsung Biologics, Siemens, Abbott Laboratories, Anheuser-Busch, Whirlpool, Rolls-Royce, Philips, ABB, JBS USA, Pratt & Whitney, and many others—have also announced new manufacturing plants, technology facilities, or infrastructure investments across the country.

Supporters say the scale of the announcements reflects a broader trend of reindustrialization and renewed domestic manufacturing capacity, with hundreds of thousands of jobs expected to be created.

Economic analysts note that many large corporate investment decisions span several years and multiple administrations, but the administration’s backers argue the surge signals strong confidence in the American economy and workforce.

More investment announcements are expected as companies continue expanding U.S. operations.

Source link

Manufacturers Expand U.S. Operations With New Plants and Investments

Several major companies are ramping up manufacturing investments across the United States, announcing new facilities, production expansions and job creation as firms strengthen domestic supply chains and meet rising demand in sectors such as pharmaceuticals, steel and advanced electronics.

Courtesy: Photo by Josh Olalde on Unsplash

Industry leaders including Novartis, US Forged Rings, Akston Biosciences and Faith Technologies have recently revealed projects spanning multiple states, highlighting continued momentum in U.S. manufacturing development.

These investments come as companies seek to expand production capacity, shorten supply chains and support growing demand for high-tech products and industrial materials.

Novartis Plans New Cancer Treatment Facility in Texas

Pharmaceutical giant Novartis is planning to build a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, as part of its wider effort to expand research and manufacturing operations in the United States.

The new plant will focus on producing targeted treatments for patients with advanced cancers and will become the company’s fifth U.S. site dedicated to radioligand therapy manufacturing.

Construction on the project is expected to begin in 2026, with commercial production anticipated to start by 2028.

The Denton facility represents part of Novartis’ broader $23 billion commitment to expand its U.S. manufacturing and research footprint, which the company announced last year.

Over the past 10 months, the pharmaceutical company has already broken ground on four additional facilities across the country, demonstrating continued progress toward that long-term investment strategy.

The Texas project is expected to create jobs in several specialized fields including:

• Bioengineering
• Advanced manufacturing
• Quality control
• Operations management

Local officials say the project could generate new opportunities for the regional biotechnology workforce while supporting broader economic growth.

The investment in Denton is estimated at $280 million and may qualify for nearly $9 million in state and local tax incentives, according to local reports.

US Forged Rings Plans Major Steel Production Facility

Startup steel manufacturer US Forged Rings has selected Hertford County, North Carolina, as the location for a large-scale industrial production facility focused on steel forgings and industrial components.

The project is part of a three-phase development plan valued at approximately $875 million.

The first two phases alone are expected to create 625 new jobs in the region while supporting growth in domestic steel production.

“This investment represents an important step in our mission to strengthen American manufacturing capability in critical steel products,” US Forged Rings President and CEO Giacomo Sozzi said in a statement.

Founded in 2022, the company is part of the Sozzi family’s industrial group, which has more than four decades of experience in steel forging operations.

Once operational, the facility will produce specialty tubular products and forged components used in sectors such as power generation and heavy industry.

The plant will also manufacture industrial parts including:

• Forged rings
• Shafts
• Cylinders

The site will be located next to a steel plant operated by Nucor, a key supply chain partner for the project. Rail services will be provided by CSX Transportation to support long-distance freight shipments.

Production for the first phases is expected to begin in 2028.

Additional Manufacturing Projects Expand Across the U.S.

Several other companies are also expanding their manufacturing presence with new facilities and production investments.

Animal health biotech company Akston Biosciences has opened a 31,000-square-foot manufacturing plant in Shreveport, Louisiana, marking a key milestone in its expansion strategy.

The facility is part of a $7 million investment aimed at increasing production of protein therapeutics designed for pet health treatments.

The site is expected to create 69 direct jobs over the next five years, with average annual salaries of around $100,000, according to local economic development officials.

Akston co-founder and CEO Todd Zion described the project as a significant step for the company’s growth.

“major milestone,” saying that it was critical to expand in the U.S. and aims to address unmet needs in pet health with its protein therapeutics.

The facility includes specialized infrastructure such as clean rooms for biologics production, quality control laboratories, cold storage systems and warehouse space.

Meanwhile, electrical equipment manufacturer Faith Technologies is planning to invest $79 million in a new production facility in Opelika, Alabama.

The project involves renovating a former distribution center previously used by Joann Fabrics.

Once completed, the site is expected to create around 200 jobs in the Auburn-Opelika metropolitan area.

Courtesy: Photo by Aleksey on Pexels

Faith Technologies manufactures electrical systems including switchboards, power modules and charging infrastructure used in energy, construction and technology markets.

The company’s modular electrical solutions are also designed for large data center developers and industrial customers, a rapidly growing segment of the construction and technology industries.

Domestic Manufacturing Momentum Continues

The wave of new investments reflects a broader trend toward reshoring manufacturing operations in the United States.

Companies are increasingly prioritizing domestic production to improve supply chain resilience, reduce shipping delays and respond more quickly to market demand.

At the same time, federal and state incentives, growing demand for advanced technologies and expanding infrastructure projects are encouraging firms to build new facilities across the country.

As industries such as pharmaceuticals, energy, electronics and advanced materials continue to grow, analysts expect manufacturing investment in the U.S. to remain strong in the coming years, with more companies announcing expansion plans and new production hubs.

Originally reported by Nathan Owens, Reporter in Manufacturing Dive.

Source link

Factbox-Global drugmakers rush to boost US presence as tariff threat looms | WKZO | Everything Kalamazoo

March 9 (Reuters) – Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

Here’s what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer

Pfizer reached a deal with President Donald ​Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK

The London-based drugmaker plans to invest $30 billion in ‌U.S. research and development and supply chain infrastructure over five years.

Eli Lilly

U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.

Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.

Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.

Johnson & Johnson

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies’ manufacturing site in Holly Springs, North ‌Carolina, over ​the next 10 years.

The company said in February it would invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of ⁠its larger plans announced last year to scale up U.S. manufacturing.

Roche

The ⁠Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions ​in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be “very short-lived.”

Novartis

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 ⁠jobs.

Sanofi

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to ⁠expand its U.S. manufacturing capacity through direct investments in the company’s sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are ​expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The ​company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia ‌as part of its over $70 billion investment to expand domestic manufacturing and research and development.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.

Merck’s animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total ⁠investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk

The Danish ⁠pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for ‌tariff challenges, describing itself as “very U.S.-centric and U.S.-focused”.

AbbVie

U.S. drugmaker AbbVie said in January it has committed $100 billion over the next decade to U.S.-based research and development as ⁠part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is “fairly insulated” from ​any tariff impact this ‌year, given inventory management actions.

The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, ​Illinois, campus, to support the ⁠production of its neuroscience and obesity medications.

Gilead Sciences

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.

CSL

Australia’s CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing ​by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)

Source link

GE Aerospace : to Invest Another $1B in U.S. Manufacturing

• Investment will help customers by accelerating engine deliveries, ramping parts that extend time-on-wing, and strengthening defense production and supplier base

• Hiring additional 5K U.S. workers in 2026

CINCINNATI – March 9, 2026 – GE Aerospace plans to invest another $1 billion in its U.S. manufacturing sites and supplier base during 2026 to help accelerate engine deliveries, ramp production of parts that safely extend time between maintenance shop visits, and strengthen defense production to keep pace with military demand.

The 2026 investment-the company’s second consecutive $1 billion U.S. investment-will benefit sites across more than 30 communities in 17 states. GE Aerospace also plans to hire 5,000 U.S. workers, including both manufacturing and engineering roles, in addition to the 5,000 people it hired last year. View an interactive map of planned investments: https://www.geaerospace.com/manufacturing

“Maintaining U.S. aerospace leadership requires sustained investment in our people, our facilities, and the technologies that will define the future of flight,” said H. Lawrence Culp, Jr., Chairman and CEO of GE Aerospace. “This investment is for our customers, our communities, and our country.”

Since 2024, GE Aerospace has announced plans to invest more than $2.5 billion across its U.S. manufacturing sites and supplier base, including approximately $600 million in sites producing defense engines during the last three years. This manufacturing investment is in addition to the nearly $3 billion GE Aerospace invests annually in research and development.

Accelerating Deliveries
The investment expands capacity at sites producing and assembling commercial and defense engines. This includes $115M in Cincinnati, Ohio-home to GE Aerospace’s headquarters- to modernize infrastructure, increase test cell capacity, and expand advanced 3D metal printing capabilities.

Defense
More than $275 million of the $1 billion is planned to upgrade sites producing defense engines and components, helping to strengthen the U.S. defense industrial base to deliver at pace for the warfighter’s evolving needs. Highlights include:
• $40+ million for Lynn, Mass., to refresh machinery, expand test cell capacity and flexibility to meet delivery pace, and make building upgrades.
• $10 million for Madisonville, Ky., to invest in new machines increasing part production, inspection equipment, tooling, and facility upgrades.

Commercial
The company is expanding commercial engine production capacity, particularly the CFM LEAP engine that powers the Boeing 737MAX and Airbus A320 aircraft families. These investments will increase part production for maintenance sites, helping reduce turnaround times. Highlights include:
• $200 million to expand manufacturing capacity for LEAP high-pressure turbine durability kits that will improve time-on-wing for customers by more than two times in hot and harsh conditions. The investment also supports production of the reverse bleed system, which reduces the need for on-wing maintenance.
• $20 million for Durham, N.C., for specialized tooling, engine line assembly systems, and building upgrades to support the increased assembly of narrowbody and widebody engines.
• $7 million for Lafayette, Ind., in new tools, equipment, and facility upgrades that support engine assembly and increase capacity to meet 2026 narrowbody engine deliveries.

Investing in Supply Chain
GE Aerospace is investing more than $100 million, as part of the $1 billion, in its external supplier base. These funds will provide tooling and equipment to help stabilize production schedules-critical to meeting delivery commitments. Deploying these investments alongside FLIGHT DECK, the company’s proprietary lean operating model, already have helped improve material input last year by more than 40 percent from priority suppliers compared to the previous year. This, in turn, drove commercial engine deliveries up 25 percent and defense engine deliveries up 30 percent in 2025 compared to the previous year.

Investing in U.S. Workforce
Today’s hiring news builds on GE Aerospace’s announcement last fall of a new, $30-million GE Aerospace Foundation program to train 10,000 workers by 2030 with the manufacturing skills to support the entire industry.

*CFM LEAP engines are made by CFM International, a 50-50 joint company between GE Aerospace and Safran Aircraft Engines.

###

About GE Aerospace
GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 50,000 commercial and 30,000 military aircraft engines. With a global team of approximately 57,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow, and the future at www.geaerospace.com.

Source link

Japan, US Consider $13B Display Manufacturing Plant Partnership

The United States and Japan are exploring a partnership to construct a display manufacturing facility on American soil as part of Japan’s $550 billion investment commitment. The collaboration with Japan Display aims to reduce U.S. dependence on Chinese display technology for military applications.

Government officials from the United States and Japan are exploring the possibility of establishing a display manufacturing facility on American soil through a collaboration with Japan Display, according to two informed sources who spoke Monday.

This potential partnership would fall under Japan’s comprehensive $550 billion investment commitment and represents an effort to reduce America’s dependence on Chinese-made display technology, particularly for defense applications. The move comes as intense pricing pressures have forced most Japanese display manufacturers to exit the global market.

Japan Display has chosen not to provide any statement regarding these discussions. However, the company’s stock price jumped dramatically by 80% on Monday, bringing the financially troubled firm’s market value to 190 billion yen, equivalent to approximately $1.2 billion.

According to initial reporting by Nikkei Asia, the proposed manufacturing project carries an estimated price tag of around $13 billion.

Sources familiar with the negotiations indicate this display facility represents just one element of multiple agreements currently being discussed between Washington and Tokyo. One source, speaking on condition of anonymity, confirmed the broader scope of these talks.

Previous reporting has revealed that both nations are also working to incorporate a nuclear energy initiative featuring Westinghouse into a second phase of agreements, all stemming from investment pledges Japan made as part of its trade tariff arrangement with the United States.

Japan Display originated in 2012 through a government-supported consolidation that combined the display manufacturing divisions of major corporations Sony Group, Toshiba, and Hitachi. The company previously held a position among the world’s leading liquid crystal display panel producers and served as the main screen supplier for Apple’s iPhone products.

However, Apple’s transition to organic light-emitting display technology, coupled with aggressive pricing from Chinese competitors, has resulted in Japan Display experiencing financial losses for over ten years.

Currently, the company is streamlining its Japanese manufacturing operations to concentrate resources on automotive display markets while simultaneously discontinuing OLED panel manufacturing for Apple Watch devices.

The Japanese government previously invested more than 460 billion yen in Japan Display before divesting its stake last year, ultimately losing approximately one-third of its total investment.

Industry analysis firm Counterpoint projects that China will maintain its dominance in worldwide display manufacturing capacity, with its market share expected to grow from 68% in 2023 to 75% by 2028.

Source link

HD Hyundai Electric expands US transformer manufacturing capacity

VIPs pose during a groundbreaking event for HD Hyundai Electric’s second plant in Montgomery, Ala., Friday (local time). Third from left are Montgomery City Council President Cornelius Calhoun, HD Hyundai Electric CEO Kim Young-ki, Korean Consulate General in Atlanta Lee Jun-ho, HD Hyundai Electric Vice Chairman Cho Seok and Alabama Department of Commerce Secretary Ellen McNair. Courtesy of HD Hyundai Electric

HD Hyundai Electric is strengthening its presence in the North American market, expanding its manufacturing capacity in the United States.

The company said Sunday that it held a groundbreaking ceremony in Montgomery, Alabama, Friday (local time), for the second plant of HD Hyundai Power Transformers USA, its North American manufacturing subsidiary.

The new facility, scheduled to be completed in April next year, will span 29,000 square meters within the existing Montgomery site.

By investing $200 million, the company will expand its ultra-high-voltage transformer production capacity by 50 percent and establish new testing and production lines for 765-kilovolt transformers, a key component seeing rising demand as the U.S. pushes to add high-voltage backbone transmission networks to its power grid.

Once completed, the new plant is expected to generate roughly 200 billion won ($134.68 million) in additional annual revenue.

“The North American manufacturing subsidiary has played a pivotal role in strengthening our foothold in the U.S. market through localized manufacturing,” a company official said.

“With the successful completion of the second plant and additional expansion at our Ulsan facility scheduled for September, we expect to further reinforce our leadership in the North American ultra-high-voltage transformer market.”

Established in 2011, HD Hyundai Power Transformers USA is the first transformer manufacturing facility built in the U.S. by a Korean electrical equipment company and remains the largest production site for power transformers in the country.

The company has steadily expanded its investment into the site over the past decade, initially investing 62.6 billion won to establish the plant and adding 53.7 billion won to boost capacity in 2018. In 2023, it added a dedicated transformer storage facility with an 18.3 billion won investment.

The regional manufacturing base has helped shorten delivery lead times and improve customer responsiveness, reinforcing its credibility and competitiveness in the market.

As a result, its U.S. operation has been seeing steady growth with the subsidiary’s annual revenue climbing from about $100 million in 2017 to roughly $400 million last year. Its workforce also expanded from 100 in 2011 to about 460 in 2025. The company plans to hire about 200 additional workers once the second plant is completed.

Source link

US-Israel-Iran Conflict: The Manufacturing Impacts

Air freight capacity

The conflict has severely impacted air freight capacity, with data from Netherlands-based consultancy Rotate showing global air cargo capacity down 18% from the previous week.

Emirates SkyCargo, the fourth-largest cargo airline by traffic, suspended flights until 3:00pm UAE time on March 2, while also placing temporary restrictions on booking and acceptance of all new shipments for 24 hours.

FedEx suspended flights to and from Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, United Arab Emirates and Saudi Arabia, with pickup and delivery services in several of these markets temporarily halted.

Qatar Airways, which operates 29 Boeing 777 freighter aircraft offering more than 3,000 tonnes of capacity per day, temporarily halted flights due to Qatar’s airspace closure.

The reduction in air cargo capacity has created a bottleneck for time-sensitive shipments, with pharmaceutical companies and technology manufacturers particularly affected.

Freight forwarders report that available cargo space is being prioritised for medical supplies and critical components.

Airfreight rates on key routes have reached record levels, with some shippers reporting costs exceeding pre-pandemic peaks as demand outstrips the severely constrained capacity.

Manufacturing challenges

The disruption could create particular challenges for manufacturers across multiple sectors.

Just-in-time delivery for microchips and consumer technology components has been severely disrupted, with electric vehicle (EV) batteries and semiconductors  stranded in the Gulf.

Air freight costs have reportedly spiked, affecting manufacturers dependent on components and Active Pharmaceutical Ingredients from India.

The construction sector faces delays in delivery of Chinese structural steel and specialised materials like heat-reflective glass, which cannot be airlifted.

Multiple companies are invoking force majeure clauses with potential multi-month stop-work orders on major projects.

Simon says: “Just what does happen next now depends on the intentions and actions of several actors and the composition of the next Iranian regime. But for businesses, there is a need to enact contingency plans immediately and begin working through the implications of this conflict lasting weeks or months, rather than days.”

Source link